Aligning Pharmaceutical Quality Systems and Product Development

For breakthrough product development, Pharmaceutical Quality System (PQS) requirements need to be followed while supplying suitable flexibility to suit accelerated activities for breakthrough product development timelines. Therefore, the accelerated development Pharmaceutical Quality System (PQS) strategy for each product will be unique, as it depends on the timing of the BT designation.













Image Credit: DS InPharmatics LLC

A number of activities that might be considered to accelerate development activities are:

  • Flexibility, on the basis of molecule, available product, and platform knowledge will be needed
  • Just the activities with zero impact on patient safety or product supply should be delayed
  • A quality risk assessment needs to be applied to every activity that will be delayed, and the rationale, and controls required to guarantee delayed activities are completed documented
  • A number of activities that are usually completed before license application might need to be delayed and submitted:
    • Post-submission, complete at inspection
    • Post-inspection, before approval
    • Post-market commitments
  • The manufacturing readiness plan can be employed for the development of internal filing and inspection readiness checklists to safeguard all delayed activities are completed or addressed
    • Any Pharmaceutical Quality System (PQS) deferrals need to be documented in a manufacturing readiness plan and monitored to guarantee completion

About DS InPharmatics LLC

DS InPharmatics (DSI) provides regulatory, technical, and project management consulting services to healthcare product companies that manufacture and/or market pharmaceuticals, biopharmaceuticals, and cellular and gene therapy products.

Since 2007 we have provided our clients with innovative strategies and exceptional quality work products intended to enhance product development, approval, and marketing presence. Whether advocating CMC strategy, directing CMC operations or developing CMC submission content that represent the best interests of emerging biotech, we focus on the critical CMC issues and build programs that enhance development.

Sponsored Content Policy: publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: May 21, 2021 at 9:32 AM


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    DSI, a PLG Company. (2021, May 21). Aligning Pharmaceutical Quality Systems and Product Development. News-Medical. Retrieved on April 02, 2023 from

  • MLA

    DSI, a PLG Company. "Aligning Pharmaceutical Quality Systems and Product Development". News-Medical. 02 April 2023. <>.

  • Chicago

    DSI, a PLG Company. "Aligning Pharmaceutical Quality Systems and Product Development". News-Medical. (accessed April 02, 2023).

  • Harvard

    DSI, a PLG Company. 2021. Aligning Pharmaceutical Quality Systems and Product Development. News-Medical, viewed 02 April 2023,

Other White Papers by this Supplier